Christie A, McKay N, Nussey F. Dermatomyositis as presenting feature of ovarian cancer, treated with neo-adjuvant chemotherapy and interval debulking surgery.
GYNECOLOGIC ONCOLOGY CASE REPORTS 2013;
6:13-5. [PMID:
24371708 PMCID:
PMC3862295 DOI:
10.1016/j.gynor.2013.07.002]
[Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/21/2013] [Accepted: 07/04/2013] [Indexed: 11/28/2022]
Abstract
Dermatomyositis in ovarian cancer responds to treatment with neo-adjuvant carboplatin and paclitaxel in conjunction with corticosteroids.
Recurrence of dermatomyositis symptoms is often the first sign of relapsed disease.
Prognosis of ovarian cancer in context of dermatomyositis is poor.
Collapse